Ado-trastuzumab emtansine
Established medicineAlso known as KADCYLA, T-DM1, TDM1, TRASTUZUMAB EMTANSINE+2 more
KADCYLA, T-DM1, TDM1, TRASTUZUMAB EMTANSINE, Trastuzumab-DM1, Trastuzumab-MCC-DM1.
Recent clinical, regulatory, research and industry developments relating to this drug.
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer.
Mechanisms of Resistance to Antibody-Drug Conjugates.
Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- ESMO open4
- Annals of oncology : official journal of the European Society for Medical Oncology2
- International journal of molecular sciences2
- The New England journal of medicine2
- British journal of cancer1
- Cancer communications (London, England)1
- Curigliano G5
- Kim SB5
- Cortés J4
- Im SA4
- Iwata H4
- Cathcart J3
- Hamilton E3
- Hurvitz SA3
- Asan Medical Center4
- Aichi Cancer Center Hospital3
- European Institute of Oncology3
- Seoul National University Hospital3
- Fred Hutchinson Cancer Center2
- International Breast Cancer Center (IBCC)2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 11 of the same disease areas as Ado-trastuzumab emtansine in the shared literature.
Studied across 11 of the same disease areas as Ado-trastuzumab emtansine in the shared literature.
Studied across 6 of the same disease areas as Ado-trastuzumab emtansine in the shared literature.
Studied across 7 of the same disease areas as Ado-trastuzumab emtansine in the shared literature.
Studied across 4 of the same disease areas as Ado-trastuzumab emtansine in the shared literature.
Studied across the same disease area as Ado-trastuzumab emtansine in the shared literature.
Studied across the same disease area as Ado-trastuzumab emtansine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature